Merck & Co Inc
NYSE: MRK
$99.85
-$1.17 (-1.2%)
Closing Price on January 8, 2025
MRK Articles
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Merck, Intel, JPMorgan Chase, and IBM led the Dow to a gain on Monday.
Published:
Last Updated:
Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.
Published:
Last Updated:
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Published:
Last Updated:
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Published:
Last Updated:
Merck and Walmart were among Wednesday's biggest gainers on the Dow while Intel and Cisco were among the big losers.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The Stifel view is that it is time for investors to take a more defensive posture, but that doesn’t mean selling everything and going to cash.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
The Dow dropped in Tuesday trading, led by downturns at Disney, Merck, Nike, and DowDuPont.
Published:
Last Updated:
Walmart, General Electric, Merck, and Verizon were biggest losers on the DJIA Tuesday.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
Merck reported mixed fourth-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.